Media Coverage

  • May 19, 2021
    Medipure Holdings Inc. Announces a Filing of its Provisional Patent for Psoriasis Treatment
    Vancouver, Canada (May 19, 2021) – Medipure Pharmaceuticals Inc. (“MPI”), a wholly owned subsidiary of Medipure Holdings Inc. (together with MPI, “Medipure” or the “Company”), a biopharmaceutical incubator committed to discovering and developing proprietary prescription drugs focused on the endocannabinoid system, is pleased to announce the submission of provisional patent application to the United States Patent and Trademark Office (“USPTO”) for MP-30X technology entitled “METHODS TO PRODUCE NOVEL FORMULATIONS TO TREAT INFLAMMATORY SKIN CONDITIONS” US 63/179,075 with a filing date of April 23, 2021. This invention relates to a novel topical/dermal formulation for the treatment of inflammatory skin diseases including psoriasis, psoriatic arthritis and atopic dermatitis.
    Read More
  • Mar 16, 2021
    Medipure Holdings Inc. Announces Walter Berukoff to Serve as Special Advisor to Company’s Board of Directors
    Vancouver, Canada (March 16, 2021) – Medipure Holdings Inc. announces Walter Berukoff, President of Red Lion Management and Chairman and CEO of Lion One Metals Ltd., will serve as Special Advisor to the Company’s Board of Directors. For over fifty years, Mr. Berukoff has built a solid reputation as a successful mining entrepreneur, fund and money manager, real estate developer, organic agriculture enthusiast and financier. His half century of business success has earned him lasting respect for his varied accomplishments. He will draw on his expertise and support the Board as it pertains to global banking, institutional, sovereign and family offices.
    Read More
  • Feb 25, 2021
    Medipure Holdings Inc. Announces a Milestone for its Proprietary Anxiety and Mood Disorder Medication
    Vancouver, Canada (February 25, 2021) – Medipure Pharmaceuticals Inc. (“MPI”), a wholly owned subsidiary of Medipure Holdings Inc. (together with MPI, “Medipure” or the “Company”), announces its anxiety and mood disorder drug (MP-20X, U.S. patent applications 20200253947 and 20200253948) has been issued a Notice of Allowance (“NOA”) from the United States Patent and Trademark Office (“USPTO”). As stated in the NOA, MP-20X “has been examined and is allowed for issuance as a patent. Prosecution on the merits is closed”.
    Read More
  • Feb 23, 2021
    Medipure Holdings Inc. Announces Denis J. Gallagher to Join Company’s Board of Directors
    Vancouver, Canada (February 24, 2021) – Medipure Holdings Inc., announces Denis J. Gallagher, CEO of Economic Transformation Technologies (ETT), to join its Board of Directors. Gallagher the former Founder, Chairman and CEO of Student Transportation Inc. (STB:TSX), a publicly listed transportation and logistics company based in Toronto and New Jersey, listed on the Toronto Stock Exchange in 2004 and saw a 2011 listing on the NASDAQ prior to an April 2018 go-private sale to the Caisse de dépôt et placement in Quebec its largest shareholder. In addition to his leadership skills, Gallagher brings experience in business development, corporate governance and accessing public capital markets, to assist with the future growth plans for Medipure.
    Read More
  • Jun 18, 2020
    MEDIPURE FILES INTERNATIONAL APPLICATION UNDER WIPO's PATENT COORPORATION TREATY (PCT) FOR ANXIOLYTIC FORMULATIONS
    Medipure Pharmaceuticals Inc., has filed patent applications and confirmed receipts with International Applications Under WIPO’s Patent Cooperation Treaty (PCT), an important step in providing intellectual and commercial protection for MP-20X as an endocannabinoid system-based prescription Anxiolytic medications.
    Read More
  • Feb 16, 2019
    The Medipure Newsletter - Q4 2018 Edition
    Read our Q4 2018 Edition of the Company Newsletter
    Read More
  • Feb 12, 2019
    Medipure Announces Key Addition To Take Company To Next Stage Of Development
    Medipure appoints Alan C. Mendelson as Corporate Secretary and Advisor to the Board of Directors.
    Read More
  • Feb 12, 2019
    Medipure Announces Appointment Of Renowned Croatian Health Specialist
    Medipure today announced the appointment of Dr. Ognjen Brborović to its Scientific Advisory Board.
    Read More
  • Feb 12, 2019
    Medipure Announces Key Appointment To Croatia Subsidiary
    Medipure today announced the appointment of Dr. Miroslav Weiss as Medical Director of its subsidiary in Croatia
    Read More
  • Nov 01, 2018
    The Medipure Newsletter - Q2-3 2018 Edition
    Read our Q2-3 2018 Edition of the Company Newsletter
    Read More

Pages